The "Undetermined Significance" of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
Fiche du document
23 août 2021
- doi: 10.3390/medicina57080856
- issn: 1010-660X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3390/medicina57080856
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34441062
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1648-9144
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_4CD5BD2D3C310
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Diseases--ImagingCiter ce document
G. Treglia et al., « The "Undetermined Significance" of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS). », Serveur académique Lausannois, ID : 10.3390/medicina57080856
Métriques
Partage / Export
Résumé
Monoclonal gammopathy of undetermined significance (MGUS) is a highly prevalent condition with the possible risk of progression to multiple myeloma (MM) or a lymphoproliferative neoplasm in a small percentage of patients. Fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI) are imaging methods increasingly used in patients with MM. The aim of this communication is to underline that, taking into account current evidence-based data, compared to MM the role of 18 F-FDG PET/CT or PET/MRI in MGUS is still undetermined and more studies should be performed before suggesting 18 F-FDG PET/CT or PET/MRI for evaluation of MM progression in patients with MGUS.